Intervacc AB (IVACC) AI Stock Analysis

• Market Cap: kr306.73M
• Dividend Yield: N/A
• Average Volume (3M): 373.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 127.13%
• EPS Growth: 56.91%
• Country: SE
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 340,813,200
• 10 Day Avg. Volume: 453,808
• 30 Day Avg. Volume: 373,337
• PEG Ratio: 0.03
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 7.49
• P/FCF Ratio: -1.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: kr0.92 ▲(4.77% Upside)

Intervacc AB's overall stock score reflects significant financial challenges, including persistent losses and negative cash flows. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. The company's low leverage is a minor positive, but strategic improvements are needed to enhance financial health.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust market demand and successful product adoption, which can lead to increased market share and long-term business sustainability.

Low Leverage

Minimal leverage reduces financial risk and enhances the company's ability to invest in growth opportunities without the burden of high interest obligations.

Free Cash Flow Alignment

Positive alignment between free cash flow and net income suggests efficient cash management, supporting sustainable operations and potential reinvestment in the business.

Negative Factors

Negative Margins

Negative margins indicate cost management issues and operational inefficiencies, which can hinder profitability and long-term financial health.

Cash Flow Challenges

Persistent cash flow challenges can constrain the company's ability to fund operations and growth initiatives, potentially impacting future performance.

Negative Return on Equity

Negative return on equity reflects poor returns for shareholders, indicating inefficiencies in utilizing equity capital to generate profits.

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.

How the Company Makes Money

Intervacc AB generates revenue through the development and commercialization of its vaccine products. The company typically earns income by selling its vaccines directly to veterinary clinics and animal health distributors, as well as through partnerships with larger pharmaceutical companies that may license its vaccine technologies. Additionally, IVACC may receive funding from research grants and collaborations aimed at advancing its vaccine research and development projects. Significant partnerships with industry leaders can also enhance its market presence and contribute to revenue growth through shared resources and joint marketing efforts.

Intervacc AB Financial Statement Overview

Summary

Intervacc AB faces significant financial challenges, characterized by persistent losses and negative cash flows. Despite revenue growth, profitability and cash management remain weak. Low leverage is a positive aspect, but the inability to generate positive returns and cash flow is critical.

Income Statement

Intervacc AB shows a consistent pattern of negative profitability, with a TTM net profit margin of -390.34% and a gross profit margin of -5.45%. Despite a revenue growth rate of 15.61% in the TTM, the company is struggling to convert this into positive earnings, as evidenced by negative EBIT and EBITDA margins. The persistent negative margins indicate significant challenges in managing costs relative to revenue.

Balance Sheet

The company's balance sheet reflects low leverage with a debt-to-equity ratio of 0.00027, indicating minimal reliance on debt financing. However, the return on equity is negative at -28.20%, highlighting inefficiencies in generating returns for shareholders. The equity ratio stands at a healthy level, suggesting a strong capital structure, but the negative ROE remains a concern.

Cash Flow

Intervacc AB's cash flow statement reveals a challenging cash position, with negative operating cash flow and free cash flow. The free cash flow growth rate of 30.25% in the TTM is a positive sign, yet the operating cash flow to net income ratio of -1.43 indicates difficulties in converting earnings into cash. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.94M	11.79M	8.02M	9.68M	5.24M	4.78M
Gross Profit	-52.47M	-3.53M	-13.81M	3.37M	6.25M	4.64M
EBITDA	-112.29M	-58.75M	-68.98M	-57.73M	-23.15M	-19.39M
Net Income	-155.25M	-75.52M	-102.85M	-64.16M	-29.38M	-25.60M
Balance Sheet
Total Assets	329.23M	187.32M	259.61M	265.04M	329.39M	355.28M
Cash, Cash Equivalents and Short-Term Investments	172.36M	34.40M	88.34M	45.70M	115.71M	164.25M
Total Debt	78.00K	145.00K	181.00K	322.00K	433.00K	383.00K
Total Liabilities	18.76M	24.99M	21.68M	14.88M	21.14M	17.67M
Stockholders Equity	310.46M	162.33M	237.93M	250.16M	308.25M	337.61M
Cash Flow
Free Cash Flow	-200.06M	-53.90M	-47.94M	-75.92M	-48.67M	-31.50M
Operating Cash Flow	-197.64M	-53.20M	-45.83M	-69.79M	-25.46M	-20.08M
Investing Cash Flow	-2.42M	-706.00K	-2.11M	-6.13M	-23.13M	-11.27M
Financing Cash Flow	386.79M	-36.00K	90.58M	5.91M	50.00K	143.06M

Intervacc AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 0.90, below the 50-day MA of 0.95, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.59 is Neutral, neither overbought nor oversold. The STOCH value of 54.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	48 Neutral	kr228.68M	1.21	-16.90%	―	4.64%	―
ELIC	47 Neutral	€270.83M	-15.98	-48.30%	―	―	52.96%
IMMU	47 Neutral	€302.73M	-2.48	-16.51%	―	―	31.37%
IVACC	45 Neutral	kr306.73M	-2.33	-25.66%	―	127.13%	56.91%
ACE	43 Neutral	kr380.61M	-3.55	-79.60%	―	―	31.62%
IRLAB.A	40 Underperform	kr164.10M	-1.24	-199.86%	―	69.03%	23.10%